ArticlePloS one2025
Plasma-activated water modulates taxanes production and phenylalanineammonia-lyase activity in Taxus baccata cell culture.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paclitaxel, an anti-cancer compound from the Taxus baccata L. (yew tree), is limited in availability from natural sources. This study explores the use of plasma-activated water (PAW) as an elicitor in T. baccata suspension cell cultures to enhance the production of paclitaxel and its precursor, 10-Deacetylbaccatin III (10-DAB III). The effects of PAW on various factors, including fresh and dry weight, cell viability, and phenylalanine ammonia-lyase (PAL) activity were investigated. The PAW treatment was conducted at different concentrations (200, 300, and 400 μL), with a pH of 5.6 to 5.8, and was applied at different time points (0, 7, 14, and 21 days). The results revealed that 10-DAB III was increased (14.04 µg/g) significantly at a concentration of 400 μL of PAW on day 21. In contrast, the highest paclitaxel content (3.342 µg/g) was achieved in the control group on day 21. The PAW treatment reduced cell viability by 32.25% compared to day 0 (86.25%), and PAL activity increased initially before declining, but remained higher than in the control group. This study is the first to demonstrate the potential of PAW to enhance taxanes production in T. baccata cell cultures, warranting further investigation into the underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.